Memorial Sloan Kettering swings to $339.1M operating income through Q3: 6 things to know

Advertisement

New York City-based Memorial Sloan Kettering Cancer Center recorded operating income of $339.1 million (4.9% operating margin) through the third quarter of 2026, up from an operating loss of $174.9 million (-2.8% margin) during the same period last year, according to its Nov. 13 financial report.

Six things to know: 

1. MSK reported total operating revenue of $7 billion for the nine months ended Sept. 30, up from $6.2 billion during the same period last year. Hospital care and services revenue totaled $5.9 billion, up from $5.2 billion. The system attributed the growth to higher patient revenue and one-time items, including $57.3 million in COVID-19 relief funding and $35.9 million in settlement payments. The prior-year period included $27.9 million in COVID-19 relief funding.

2. Total operating expenses were $6.6 billion, up from $6.4 billion. The prior-year period included $169.5 million in incremental expenses tied to MSK’s Epic EHR go-live in February 2025. Excluding those costs, expenses increased $409.8 million, which MSK said was driven primarily by personnel costs and higher pharmaceutical expenses. Compensation and fringe benefits totaled $3.3 billion, up from $3.2 billion. Purchased supplies and services totaled $2.9 billion, up from $2.7 billion.

3. Excluding COVID-19 relief funding and one-time settlement payments, MSK’s adjusted operating income was $245.9 million (3.6% margin), compared to an adjusted operating loss of $202.8 million (-3.3% margin) during the same period last year.

4. Clinic visits totaled 587,062, up from 560,300 during the same period last year. Chemotherapy treatments totaled 273,497, up from 251,797, and surgical cases totaled 23,589, up from 22,345. Telemedicine visits totaled 282,260, up from 239,707. Inpatient days totaled 140,244, up from 137,727, while average length of stay was 7 days, down from 7.2.

5. MSK’s case mix index was 2.71, up from 2.57. Commercial payers accounted for 63% of patient revenue, up from 61%, while Medicare accounted for 32%, up from 31%. Medicaid accounted for 4%, down from 6%.

6. MSK reported net income of $1.1 billion through the third quarter of 2026, up from $296.8 million during the same period last year. Investment returns totaled $709.4 million, up from $454.2 million. 

Advertisement

Next Up in Financial Management

Advertisement